Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road SW
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
stocks
Major ASX miner reduces aluminium exposure
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,993.00 | 50.50 | -0.56% |
| CAC 40 | 8,479.87 | 28.20 | -0.33% |
| DAX 40 | 25,817.89 | 38.58 | 0.15% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,651.77 | 27.26 | -0.26% |
| HKSE | 23,520.33 | 95.99 | -0.41% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 68,184.93 | 1,552.76 | -2.23% |
| NZX 50 Index | 13,762.79 | 0.31 | -0.00% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,790.00 | 49.40 | -0.56% |
| SSE Composite Index | 3,989.87 | 51.37 | -1.27% |